Zota Health Care Reports 92% Q2FY26 Revenue Growth

Q2FY26 presentation highlights revenue expansion

Zota Health Care Ltd. reported 92% year-on-year growth in consolidated revenue for Q2FY26, according to its investor presentation submitted to the National Stock Exchange under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. The company attributed the growth to its strategic expansion. Zota Health Care is listed on the NSE under the trading symbol ZOTA. The disclosure presents operating and financial indicators from the quarter, including EBITDA and customer footfalls. It also reiterates the role of Davaindia, the company’s retail generic pharmacy chain, in its healthcare business. The presentation was provided for stakeholder information and was not an offer or invitation to subscribe to the company’s securities.

EBITDA stood at ₹7.96 crore

The company reported EBITDA of ₹7.96 crore in Q2FY26. EBITDA is a measure of earnings before interest, tax, depreciation and amortisation, and is commonly used to assess operating performance. Zota Health Care did not provide further profitability details in the supplied presentation excerpt, such as margins or a comparable prior-year EBITDA figure. Therefore, the available disclosure establishes the reported quarterly EBITDA level but does not support an assessment of margin movement. The 92% consolidated revenue growth and ₹7.96 crore EBITDA are the key financial figures stated in the Q2FY26 update.

Quarterly footfalls crossed 43 lakh

Quarterly footfalls at the company’s retail operations rose to 43.53 lakh in Q2FY26. This was more than double the 22.23 lakh footfalls reported for Q2FY25. The footfall increase accompanied the company’s stated strategic expansion and provides an operational measure alongside the revenue growth. Higher store visits indicate a larger volume of consumer interactions across the retail network during the reported quarter. The presentation does not provide a split of footfalls by geography, store format, or product category. It also does not state the number of operating stores in the excerpt provided.

Davaindia remains central to the retail model

Davaindia was launched in 2017 as a retail generic pharmacy chain. Zota Health Care describes the chain as offering quality generic medicines across more than 2,000 SKUs. The business model is positioned around direct retail access to generic medicines, reducing reliance on traditional intermediary layers. The supplied material says Davaindia offers discounts of up to 90% to consumers. That affordability proposition is a defining element of the chain’s market positioning. Zota Health Care has also described Davaindia in prior investor presentations as India’s largest private generic pharmacy retail chain.

Company background and listed status

Zota Health Care was established in 2000 and is headquartered in Surat, according to its investor presentations. The company has stated that it has built a significant presence in the Indian healthcare sector since inception. An August 2024 presentation said the company employed more than 400 professionals. Its registered office is at Zota House, Hira Modi Street, Sagrampura, Surat. The company’s continuing exchange disclosures identify ZOTA as its trading symbol. Its investor presentations have been submitted through the NSE listing framework under Regulation 30.

Key figures from the available disclosure

Why footfall growth matters for the business

For a pharmacy retailer, footfalls are a relevant operating indicator because they reflect the number of customer visits to the retail network. In Zota Health Care’s case, the move from 22.23 lakh footfalls in Q2FY25 to 43.53 lakh in Q2FY26 coincided with the reported 92% growth in consolidated revenue. The figures show that the reported financial expansion was accompanied by a substantial increase in retail activity. However, the provided information does not disclose average transaction values, same-store sales, prescription volumes, or online sales. It therefore does not allow a detailed breakdown of the drivers behind revenue growth.

Generic medicines and consumer access

Generic medicines are central to Davaindia’s retail offering. The company’s stated focus on direct consumer sales and discounts of up to 90% places affordability at the centre of the chain’s proposition. Its portfolio of more than 2,000 SKUs indicates coverage across a broad range of generic medicine products. The available presentation does not specify which therapeutic categories contributed most to sales or footfalls in Q2FY26. It also does not provide product-level pricing or the share of revenue generated by Davaindia. Still, the retail chain is consistently identified as a major business vertical in the company’s presentations.

What investors can take from the update

The Q2FY26 presentation provides two clear operating signals: consolidated revenue grew 92% year on year and quarterly footfalls more than doubled. EBITDA of ₹7.96 crore adds a reported profitability measure for the quarter. These data points should be read alongside the limits of the supplied disclosure, which does not include quarterly revenue in absolute terms, EBITDA margins, store additions, or segment-wise financial results. Zota Health Care’s future exchange filings and investor presentations will provide the next official updates on its financial and operating performance. For now, the company’s Q2FY26 disclosure highlights expansion-led growth at its generic pharmacy retail business.